Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Lead-in Phase II Multicentre, Randomised, Double-Blind Study Comparing AZD1775 Plus Docetaxel and Placebo Plus Docetaxel in Previously Treated Non-Small-Cell Lung Cancer Patients

NCT02087176 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT02087176
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02087176 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Lead-in Phase II Multicentre, Randomised, Double-Blind Study Comparing AZD1775 Plus Docetaxel and Placebo Plus Docetaxel in Previously Treated Non-Small-Cell Lung Cancer Patients
Lead sponsor
AstraZeneca
Phase
Phase 2
Overall status
Terminated
Start date
March 31, 2014
Completion date
May 31, 2015
Enrollment
48 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

previously treated non small cell lung cancer